The Latest Cardiac and Vascular News
TORONTO, May 8, 2018 /PRNewswire/ – A recent study published in Heart and Vessels has found that the use of the Baylis Medical NRG® radiofrequency (RF) Transseptal Needle for transseptal punctures was linked to a 40% lower incidence of silent acute cerebral embolism in atrial […]
BOSTON, May 2, 2018 /PRNewswire/ — Medicalgorithmics, S.A. (WSE: MDG) today announced the presentation of a large study evaluating online vs offline ECG monitoring methods to diagnose paroxysmal atrial fibrillation (AF), often difficult to detect because of its episodic nature. Research will be […]
VANCOUVER, April 17, 2018 /PRNewswire/ – Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced completion of enrollment for the Phase 4 SPECTRUM study evaluating Brinavess® (vernakalant hydrochloride, IV), the Company’s antiarrhythmic drug for the rapid […]
CLEVELAND–(BUSINESS WIRE)–Sotera Medical Corp., a medical device company developing a novel device for use in cardiac procedures to treat atrial fibrillation, has closed initial seed funding in excess of one million dollars. The round was led by a syndicate of […]
MARLBOROUGH, Mass., Oct. 2, 2017 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced a definitive agreement to acquire Apama Medical Inc., a privately-held company that is developing the Apama Radiofrequency (RF) Balloon Catheter System for the treatment of atrial fibrillation (AF). […]
NEWS PROVIDED BY Janssen Pharmaceuticals, Inc. | 03 Apr, 2017, 08:00 ET TITUSVILLE, N.J., April 3, 2017 /PRNewswire/ — Janssen Pharmaceuticals, Inc. (Janssen) today announced it has collaborated with Premier Inc. on the first and largest study of its kind to address […]
Press Release DUBLIN – March 30, 2017 – Medtronic plc (NYSE: MDT) today announced first enrollments in the STOP Persistent AF clinical trial. The trial will evaluate the safety and effectiveness of a pulmonary vein isolation-only (PVI) strategy for treating patients with […]
